Mersana Therapeutics Inc. (MRSN)
Company Description
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need.
It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma.
The company also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development candidate.
It has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer.
The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005.
Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.
| Country | United States |
| IPO Date | Jun 28, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 102 |
| CEO | Dr. Martin H. Huber M.D. |
Contact Details
Address: 840 Memorial Drive Cambridge, Massachusetts United States | |
| Website | https://www.mersana.com |
Stock Details
| Ticker Symbol | MRSN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001442836 |
| CUSIP Number | 59045L106 |
| ISIN Number | US59045L1061 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Martin H. Huber M.D. | President, Chief Executive Officer & Director |
| Alejandra Veronica Carvajal J.D. | Senior Vice President, Secretary & Chief Legal Officer |
| Brian C. DeSchuytner | Senior Vice President, Chief Financial Officer & Chief Operating Officer |
| Ashish Mandelia | Vice President & Chief Accounting Officer |
| Chuck Miller | Senior Vice President of Regulatory Affairs |
| Dr. Marc Damelin Ph.D. | Exe. Director and Head of Biology, Oncology, Antibody-Drug Conjugate ADC Discovery & Develop. |
| Dr. Mohan Bala Ph.D. | Senior Vice President & Chief Development Officer |
| Dr. Timothy B. Lowinger Ph.D. | Senior Vice President and Chief Science & Technology Officer |
| Jason Fredette | Senior Vice President of Investor Relations & Corporate Communications |
| Mikhail Papisov Ph.D. | Co-Founder |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 02, 2025 | 8-K | Current Report |
| May 15, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| May 15, 2025 | SCHEDULE 13G | Filing |
| May 15, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| May 15, 2025 | 10-Q | Quarterly Report |
| May 15, 2025 | 8-K | Current Report |
| May 06, 2025 | 8-K | Current Report |
| Apr 30, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Apr 29, 2025 | ARS | Filing |
| Apr 29, 2025 | DEFA14A | Filing |